Twist Bioscience misses earnings despite revenue beat By Investing.com

Twist Bioscience reported Q2 fiscal 2026 EPS of -$0.71, missing the -$0.48 consensus by $0.23, while revenue came in at $110.72 million versus $107.65 million expected. The top-line beat was offset by the wider-than-expected loss, and shares fell 0.48% in pre-market trading. The company also highlighted its early-access launch of Complex Genes, expanding its clonal genes portfolio.

Analysis

TWST’s print reinforces a familiar but important setup: this is still a story about scale leverage not yet showing up in the P&L. The revenue beat suggests demand is intact, but the market is effectively pricing the company on whether its newer, higher-complexity offerings can lift gross margin and utilization enough to narrow losses over the next 2-3 quarters. Until that operating leverage becomes visible, every incremental dollar of growth risks being treated as lower-quality because the burn remains stubborn.

The second-order winner is likely customers and adjacent tool providers tied to complex gene synthesis and nucleic-acid workflows, as Twist is signaling that demand for harder sequences is rising faster than the economics are improving. That can pressure smaller private competitors with weaker manufacturing scale or lower yield, while benefiting platform-adjacent names that sell into the same R&D budget but with better near-term margin conversion. If the Complex Genes rollout gains traction, the competitive moat is less about product breadth and more about execution speed and failure rates at scale.

Near-term risk is that the market extrapolates a single quarter’s margin miss into a longer de-rating cycle, especially if management continues to prioritize growth and product expansion over near-term profitability. The stock likely trades on the next 1-2 quarters of evidence around gross margin inflection and whether operating expenses can be held below revenue growth. A reversal would require either a clear margin step-up from the new product mix or a visible acceleration in high-value therapeutic demand that changes the revenue quality narrative.

The contrarian angle is that the miss may be over-penalized if investors are focusing too much on EPS noise and not enough on mix evolution. In tools and life sciences, the market often waits for one or two quarters of proof before re-rating, so the optimal entry may be on post-earnings weakness rather than pre-empting the turn. But if the company needs multiple quarters to monetize the new offering, the stock remains a show-me story and can drift lower on any sign of sluggish adoption.

Key Decisions for Investors

• Hold off on outright long exposure in TWST for 2-3 weeks; let the post-earnings de-risking wash out and reassess after management commentary and peer read-throughs on demand quality.
• If TWST sells off another 5-8%, consider a starter long via call spreads 3-6 months out; the thesis is a margin-reacceleration rerate, with defined downside versus stock ownership.
• Pair trade: long a better-profitable life-science platform name against TWST on a relative-value basis; TWST is more sensitive to delayed operating leverage while peers with stronger FCF can absorb any sector wobble.
• Watch for confirmation in the next two quarters: if gross margin expands and opex growth slows below revenue growth, add aggressively; if not, treat any bounce as tactical and fade rallies into earnings.